Quantitative Prediction of Intestinal Metabolism in Humans from a Simplified Intestinal Availability Model and Empirical Scaling Factor
Authors:
- Keitaro KadonoKKKeitaro Kadono
- Takafumi AkabaneTATakafumi Akabane
- Kenji TabataKTKenji Tabata
- Katsuhiko GatoKGKatsuhiko Gato
- Shigeyuki TerashitaSTShigeyuki Terashita
- Toshio TeramuraTTToshio Teramura
- 1 July 2010
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (7) , 1230-1237
Abstract
This study aimed to establish a practical and convenient method of predicting intestinal availability (Fg) in humans for highly permeable compounds at the drug discovery stage, with a focus on CYP3A4-mediated metabolism. We constructed a “simplified Fg model,” described using only metabolic parameters, assuming that passive diffusion is dominant when permeability is high and that the effect of transporters in epithelial cells is negligible. Five substrates for CYP3A4 (alprazolam, amlodipine, clonazepam, midazolam, and nifedipine) and four for both CYP3A4 and P-glycoprotein (P-gp) (nicardipine, quinidine, tacrolimus, and verapamil) were used as model compounds. Observed fraction of drug absorbed (FaFg) values for these compounds were calculated from in vivo pharmacokinetic (PK) parameters, whereas in vitro intestinal intrinsic clearance (CLint,intestine) was determined using human intestinal microsomes. The CLint,intestine for the model compounds corrected with that of midazolam was defined as CLm,index and incorporated into a simplified Fg model with empirical scaling factor. Regardless of whether the compound was a P-gp substrate, the FaFg could be reasonably fitted by the simplified Fg model, and the value of the empirical scaling factor was well estimated. These results suggest that the effects of P-gp on Fa and Fg are substantially minor, at least in the case of highly permeable compounds. Furthermore, liver intrinsic clearance (CLint,liver) can be used as a surrogate index of intestinal metabolism based on the relationship between CLint,liver and CLm,index. Fg can be easily predicted using a simplified Fg model with the empirical scaling factor, enabling more confident selection of drug candidates with desirable PK profiles in humans.Keywords
This publication has 39 references indexed in Scilit:
- Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass MetabolismThe Journal of Pharmacology and Experimental Therapeutics, 2006
- THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Drug Metabolism and Disposition, 2006
- Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeabilityJournal of Pharmaceutical Sciences, 2005
- Permeability Dominates in Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High PermeabilityMolecular Pharmaceutics, 2005
- Differentiation of organ availability by sequential and simultaneous analyses: Intestinal conjugative metabolism impacts on intestinal availability in humans**This study was presented in part as a report in the poster session, and as a selected paper for oral presentation (Chairs: Dr. Chong‐Kook Kim and Dr. Vinod P. Shah), at the Pharmaceutical Sciences World Congress 2004 in Kyoto (May 29–June 3, 2004).Journal of Pharmaceutical Sciences, 2005
- How significant is the role of P-glycoprotein in drug absorption and brain uptake?Drugs of Today, 2004
- Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1990
- Pharmacokinetics of quinidine and three of its metabolites in manJournal of Pharmacokinetics and Biopharmaceutics, 1984
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various speciesXenobiotica, 1980